Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zalutumumab + irinotecan
- Development stage
- Discontinued
- Lead developer
- Genmab
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Zalutumumab + irinotecan is an investigational **combination drug regimen** comprising zalutumumab, a fully human IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and irinotecan, a topoisomerase I inhibitor antineoplastic agent. Zalutumumab binds to EGFR and inhibits ligand-induced receptor activation and autophosphorylation while also inducing antibody-dependent cellular cytotoxicity (ADCC). Irinotecan acts by inhibiting topoisomerase I, leading to DNA damage and apoptosis in proliferating cells. This combination is being studied for advanced or metastatic colorectal cancer, particularly in patients who have progressed on or shortly after anti-EGFR therapies like cetuximab[2][3][4][5][9].
- Other names
- zalutumumab + irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)EGFR (Epidermal growth factor receptor)TOP1MT (Mitochondrial topoisomerase I)
Beyond the preview
Go deeper on zalutumumab + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zalutumumab + irinotecan.